InvestSMART

Avecho Biotechnology Limited (ASX:AVE)

ALERT: Price-sensitive ASX Announcement for AVE
Current share price for AVE : $0.019 -0.002 (-9.52%)+
Announcement
Release
29 Jul 2026 9:43AM
Price at Release
$0.021
Full Release
download
Summary
Avecho Biotechnology Limited reported significant progress in its Phase III insomnia program with positive interim analysis results, as recommended by an independent Data Monitoring Board. The trial involves a proprietary CBD TPM soft-gel capsule and continues towards full enrollment without increasing the sample size, marking an important milestone in reducing development risks. Financially, Avecho raised approximately $1.9 million through option exercises and received $1.98 million from the R&D Tax Incentive Scheme, strengthening its cash position to $6.6 million as of June 30, 2026. Corporate updates include the resignation of a non-executive director and the appointment of a new company secretary.
Key Points
  • Positive interim analysis in Phase III insomnia program.
  • No serious adverse events identified among participants.
  • Approximately $1.9 million raised through option exercises.
  • Received $1.98 million from R&D Tax Incentive Scheme.
  • Cash position of $6.6 million as of June 30, 2026.
  • Resignation of non-executive director Matthew McNamara.
  • Appointment of Naomi Lawrie as Company Secretary.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.